Cargando…

Targeted Approaches to T-Cell Lymphoma

The T-cell lymphomas are a rare group of Non-Hodgkin’s lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The developmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrop, Sean, Abeyakoon, Chathuri, Van Der Weyden, Carrie, Prince, H. Miles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229513/
https://www.ncbi.nlm.nih.gov/pubmed/34072040
http://dx.doi.org/10.3390/jpm11060481
_version_ 1783712994076655616
author Harrop, Sean
Abeyakoon, Chathuri
Van Der Weyden, Carrie
Prince, H. Miles
author_facet Harrop, Sean
Abeyakoon, Chathuri
Van Der Weyden, Carrie
Prince, H. Miles
author_sort Harrop, Sean
collection PubMed
description The T-cell lymphomas are a rare group of Non-Hodgkin’s lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies.
format Online
Article
Text
id pubmed-8229513
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82295132021-06-26 Targeted Approaches to T-Cell Lymphoma Harrop, Sean Abeyakoon, Chathuri Van Der Weyden, Carrie Prince, H. Miles J Pers Med Review The T-cell lymphomas are a rare group of Non-Hodgkin’s lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies. MDPI 2021-05-27 /pmc/articles/PMC8229513/ /pubmed/34072040 http://dx.doi.org/10.3390/jpm11060481 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Harrop, Sean
Abeyakoon, Chathuri
Van Der Weyden, Carrie
Prince, H. Miles
Targeted Approaches to T-Cell Lymphoma
title Targeted Approaches to T-Cell Lymphoma
title_full Targeted Approaches to T-Cell Lymphoma
title_fullStr Targeted Approaches to T-Cell Lymphoma
title_full_unstemmed Targeted Approaches to T-Cell Lymphoma
title_short Targeted Approaches to T-Cell Lymphoma
title_sort targeted approaches to t-cell lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229513/
https://www.ncbi.nlm.nih.gov/pubmed/34072040
http://dx.doi.org/10.3390/jpm11060481
work_keys_str_mv AT harropsean targetedapproachestotcelllymphoma
AT abeyakoonchathuri targetedapproachestotcelllymphoma
AT vanderweydencarrie targetedapproachestotcelllymphoma
AT princehmiles targetedapproachestotcelllymphoma